Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14845743 | 0.86 | CFTR (0.39) | CFTRP2RX3AGTR1LMNACYP1A2 | |
| SCHEMBL12745351 | 0.85 | CFTR (0.39) | CFTRAGTR1LMNACYP1A2 | |
| SCHEMBL12827228 | 0.83 | CFTR (0.37) | CFTRKDM4EALDH1A1 | |
| SCHEMBL14845744 | 0.71 | CFTR (0.39) | CFTRKDM4EALDH1A1CYP1A2 | |
| SCHEMBL12745359 | 0.70 | CFTR (0.38) | CFTRKDM4EALDH1A1 | |
| SCHEMBL13365257 | 0.67 | CFTR (0.51) | CFTRKDM4ELMNACYP1A2 | |
| SCHEMBL18891403 | 0.61 | PTGS2 (0.59) | PTGS2KDM4EALDH1A1LMNA | |
| SCHEMBL14845741 | 0.59 | CFTR (0.41) | CFTRKDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL901445 | 0.57 | PTGS2 (0.64) | PTGS2KDM4ELMNACYP1A2 | |
| SCHEMBL23717076 | 0.56 | PTGS2 (0.52) | PTGS2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885PTGS2 2090/4885P2RX3 146/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | CFTR 1/4885PTGS2 1293/4885P2RX3 144/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885PTGS2 2090/4885P2RX3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.